AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$4.95 +0.82%

+$0.04 today

Market cap
$187.82M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.97M

Average 0.29M

ANTX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

AN2 Therapeutics, Inc.NASDAQ: ANTX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ANTX compares with its peers on the latest reported figures

  • ANTX's LTM Mar 2026 revenue of $0 is the 4th highest of the 6 companies compared; the peer median is $100K.
ANTX Competitors Peer median
Revenue for ANTX and competitors
Company Period LTM YoY 3-year CAGR
QTTBQ32 Bio Inc.LTM Mar 2026$53.74M —+100.7%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$37.16M +417.6%+57.9%
IBIOiBio, Inc.LTM Jun 2026$100K -75.0%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ——
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$0 -100.0%—
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ——
Peer median (excluding ANTX) $100K-75.0%+79.3%

Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue077K000
Gross Profit0(77K)000
Gross Margin—————
Research & Development16.91M29.51M54.87M40.49M24.77M
Selling, General & Admin4.67M12.75M14.76M14.07M13.34M
Operating Expenses21.57M42.19M69.64M54.55M38.11M
Depreciation & Amortization077K69.64M54.55M0
EBITDA(21.54M)(40.88M)4.9M3.23M(35.17M)
EBITDA Margin—————
Operating Income(21.57M)(42.26M)(69.64M)(54.55M)(38.11M)
Operating Margin—————
Interest Income69K1.35M4.86M5.47M2.93M
Interest Expense0514K000
Other Income / Expenses31K1.31M4.9M3.23M2.94M
Income Before Tax(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Net Margin—————
EPS (Basic)(1.50)(2.79)(2.74)(1.72)(1.16)
EPS (Diluted)(1.50)(2.79)(2.74)(1.72)(1.16)
Weighted Avg Shares18.74M15.34M23.6M29.83M30.22M
Weighted Avg Shares (Diluted)18.74M15.34M23.6M29.83M30.22M

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Intrinsic Alpha fair value

Locked

Current Price

$4.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.